The prime editor is a fusion protein consisting of a catalytically impaired Cas9 nickase (Cas9n) and an engineered reverse transcriptase (RT). The Cas9n is guided by a prime editing guide RNA (pegRNA) ...

Continue reading about off-target effects in this story. Base and Prime Editing Offer Precision CRISPR-based systems that rely on traditional Cas nucleases like Cas9 cut through both strands of DNA ...

Prime Medicine and Beam Therapeutics had common origins in gene editing. Now they're both pursuing treatments for the same ...

The new method uses a combination of prime editing, which can directly make a wide range of edits up to about 100 or 200 base pairs, and newly developed recombinase enzymes that efficiently insert ...

Prime Medicine has been given the go-ahead by the FDA for the first human trial of its prime editing technology, which promises to deliver one-shot therapies for a range of severe genetic diseases.

GenScript has signed a licensing agreement with the Broad Institute of MIT to access Broad's Prime Editing technology. "This partnership with the Broad Institute marks an exhilarating new ...

specializes in Prime Editing-based therapies and stands at the forefront of genetic medicine innovation. The stock has declined 35% year-to-date, reflecting broader market uncertainty around early ...

The biotech unveiled a new research program in alpha-1 antitrypsin deficiency, a disease that’s also a focus for rival Beam Therapeutics.

specializes in Prime Editing-based therapies and stands at the forefront of genetic medicine innovation. The stock has declined 35% year-to-date, reflecting broader market uncertainty around ...